Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at Piper Jaffray Companies dropped their Q2 2019 earnings per share estimates for Hologic in a report released on Tuesday, October 16th. Piper Jaffray Companies analyst W. Quirk now forecasts that the medical equipment provider will post earnings per share of $0.61 for the quarter, down from their prior estimate of $0.62. Piper Jaffray Companies also issued estimates for Hologic’s FY2019 earnings at $2.57 EPS and FY2020 earnings at $2.84 EPS.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.02. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. The company had revenue of $824.00 million for the quarter, compared to the consensus estimate of $800.14 million.
Shares of Hologic stock opened at $41.27 on Wednesday. The company has a current ratio of 1.29, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Hologic has a twelve month low of $35.10 and a twelve month high of $45.09. The stock has a market cap of $11.15 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 2.01 and a beta of 0.67.
Large investors have recently added to or reduced their stakes in the business. Piedmont Investment Advisors LLC acquired a new position in Hologic in the second quarter valued at about $127,000. Amussen Hunsaker Associates LLC acquired a new position in shares of Hologic during the second quarter worth approximately $159,000. Lincoln Capital Corp acquired a new position in shares of Hologic during the third quarter worth approximately $201,000. Homrich & Berg acquired a new position in shares of Hologic during the second quarter worth approximately $204,000. Finally, Granite Springs Asset Management LLC acquired a new position in shares of Hologic during the second quarter worth approximately $206,000. Hedge funds and other institutional investors own 98.65% of the company’s stock.
In other Hologic news, Director Christiana Stamoulis sold 30,967 shares of the business’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $40.70, for a total value of $1,260,356.90. Following the transaction, the director now directly owns 66,006 shares in the company, valued at $2,686,444.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Benjamin Jordan Cohn sold 3,437 shares of the business’s stock in a transaction dated Wednesday, September 19th. The shares were sold at an average price of $41.50, for a total transaction of $142,635.50. Following the completion of the transaction, the insider now owns 16,520 shares in the company, valued at $685,580. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,661 shares of company stock worth $1,927,174. Company insiders own 0.88% of the company’s stock.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Further Reading: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.